A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption

Copyright © 2011 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 142(2012), 3 vom: 01. März, Seite 252-68
1. Verfasser: Allard, Sabine D (VerfasserIn)
Weitere Verfasser: De Keersmaecker, Brenda, de Goede, Anna L, Verschuren, Esther J, Koetsveld, Jeanette, Reedijk, Mariska L, Wylock, Carolien, De Bel, Annelies V, Vandeloo, Judith, Pistoor, Frank, Heirman, Carlo, Beyer, Walter E P, Eilers, Paul H C, Corthals, Jurgen, Padmos, Iman, Thielemans, Kris, Osterhaus, Albert D M E, Lacor, Patrick, van der Ende, Marchina E, Aerts, Joeri L, van Baalen, Carel A, Gruters, Rob A
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2012
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't AIDS Vaccines Gene Products, rev Gene Products, tat nef Gene Products, Human Immunodeficiency Virus
LEADER 01000naa a22002652 4500
001 NLM21393356X
003 DE-627
005 20231224022555.0
007 cr uuu---uuuuu
008 231224s2012 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2011.10.010  |2 doi 
028 5 2 |a pubmed24n0713.xml 
035 |a (DE-627)NLM21393356X 
035 |a (NLM)22177848 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Allard, Sabine D  |e verfasserin  |4 aut 
245 1 2 |a A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption 
264 1 |c 2012 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 12.04.2012 
500 |a Date Revised 27.02.2012 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2011 Elsevier Inc. All rights reserved. 
520 |a In a phase I/IIa clinical trial, 17 HIV-1 infected patients, stable on cART, received 4 vaccinations with autologous dendritic cells electroporated with mRNA encoding Tat, Rev and Nef, after which cART was interrupted. Vaccination was safe and feasible. During the analytical treatment interruption (ATI), no serious adverse events were observed. Ninety-six weeks following ATI, 6/17 patients remained off therapy. Although induced and/or enhanced CD4(+) and CD8(+) T-cell responses specific for the immunogens were observed in most of the patients, we found no correlation with the number of weeks off cART. Moreover, CD4(+) T-cell counts, plasma viral load and the time remaining off cART following ATI did not differ from historical control data. To conclude, the vaccine was safe, well tolerated and resulted in vaccine-specific immune responses. Since no correlation with clinical parameters could be found, these results warrant further research in order to optimize the efficacy of vaccine-induced T-cell responses 
650 4 |a Clinical Trial, Phase I 
650 4 |a Clinical Trial, Phase II 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a AIDS Vaccines  |2 NLM 
650 7 |a Gene Products, rev  |2 NLM 
650 7 |a Gene Products, tat  |2 NLM 
650 7 |a nef Gene Products, Human Immunodeficiency Virus  |2 NLM 
700 1 |a De Keersmaecker, Brenda  |e verfasserin  |4 aut 
700 1 |a de Goede, Anna L  |e verfasserin  |4 aut 
700 1 |a Verschuren, Esther J  |e verfasserin  |4 aut 
700 1 |a Koetsveld, Jeanette  |e verfasserin  |4 aut 
700 1 |a Reedijk, Mariska L  |e verfasserin  |4 aut 
700 1 |a Wylock, Carolien  |e verfasserin  |4 aut 
700 1 |a De Bel, Annelies V  |e verfasserin  |4 aut 
700 1 |a Vandeloo, Judith  |e verfasserin  |4 aut 
700 1 |a Pistoor, Frank  |e verfasserin  |4 aut 
700 1 |a Heirman, Carlo  |e verfasserin  |4 aut 
700 1 |a Beyer, Walter E P  |e verfasserin  |4 aut 
700 1 |a Eilers, Paul H C  |e verfasserin  |4 aut 
700 1 |a Corthals, Jurgen  |e verfasserin  |4 aut 
700 1 |a Padmos, Iman  |e verfasserin  |4 aut 
700 1 |a Thielemans, Kris  |e verfasserin  |4 aut 
700 1 |a Osterhaus, Albert D M E  |e verfasserin  |4 aut 
700 1 |a Lacor, Patrick  |e verfasserin  |4 aut 
700 1 |a van der Ende, Marchina E  |e verfasserin  |4 aut 
700 1 |a Aerts, Joeri L  |e verfasserin  |4 aut 
700 1 |a van Baalen, Carel A  |e verfasserin  |4 aut 
700 1 |a Gruters, Rob A  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 142(2012), 3 vom: 01. März, Seite 252-68  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:142  |g year:2012  |g number:3  |g day:01  |g month:03  |g pages:252-68 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2011.10.010  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 142  |j 2012  |e 3  |b 01  |c 03  |h 252-68